These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 26456149)

  • 1. Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura.
    Connell NT; Cheves T; Sweeney JD
    Transfusion; 2016 Feb; 56(2):354-9. PubMed ID: 26456149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A study on the significance of plasma thrombospondin1 in thrombotic thrombocytopenic purpura and the relationship between thrombospondin1 and von Willebrand factor cleaving protease (ADAMTS13)].
    Liu F; Lu GY; Dong NZ; Bai X; Su J; Ruan CG
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3190-3. PubMed ID: 16405838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absolute immature platelet count dynamics in diagnosing and monitoring the clinical course of thrombotic thrombocytopenic purpura.
    Hong H; Xiao W; Stempak LM; Sandhaus LM; Maitta RW
    Transfusion; 2015 Apr; 55(4):756-65. PubMed ID: 25370931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the ADAMTS13 activity assay improved the accuracy and efficiency of the diagnosis and treatment of suspected acquired thrombotic thrombocytopenic purpura.
    Barrows BD; Teruya J
    Arch Pathol Lab Med; 2014 Apr; 138(4):546-9. PubMed ID: 24678685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab and intermediate-purity plasma-derived factor VIII concentrate (Koate®) as adjuncts to therapeutic plasma exchange for thrombotic thrombocytopenic purpura in patients with an ADAMTS13 inhibitor.
    Pandey S; Nakagawa M; Rosenbaum ER; Arnaoutakis K; Hutchins LF; Makhoul I; Milojkovic N; Cottler-Fox M
    J Clin Apher; 2015 Feb; 30(1):50-4. PubMed ID: 25042026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombotic thrombocytopenic purpura--the role of ADAMTS13 assay in clinical practice.
    Duraković N; Radonić R; Gasparović V
    Coll Antropol; 2010 Sep; 34(3):1087-91. PubMed ID: 20977108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of 50% albumin/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura.
    O'Brien KL; Price TH; Howell C; Delaney M
    J Clin Apher; 2013 Dec; 28(6):416-21. PubMed ID: 23857424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of ADAMTS13 activity and inhibitor in the postmortem diagnosis of thrombotic thrombocytopenic purpura.
    Dwyre DM; Dursteler B; Nashelsky M; Friedman KD; Raife TJ
    J Clin Apher; 2009; 24(3):106-10. PubMed ID: 19253359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial ADAMTS13 measurements during initial plasma exchange therapy guide decisions for management of unresponsive thrombotic thrombocytopenic purpura.
    van der Veen BS; Besseling R; Hoogendoorn M
    Transfusion; 2015 Oct; 55(10):2511-5. PubMed ID: 26308736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange.
    Bentley MJ; Lehman CM; Blaylock RC; Wilson AR; Rodgers GM
    Transfusion; 2010 Aug; 50(8):1654-64. PubMed ID: 20412532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort.
    Bentley MJ; Wilson AR; Rodgers GM
    Vox Sang; 2013 Nov; 105(4):313-8. PubMed ID: 23662653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative.
    Bendapudi PK; Li A; Hamdan A; Uhl L; Kaufman R; Stowell C; Dzik W; Makar RS
    Br J Haematol; 2015 Dec; 171(5):836-44. PubMed ID: 26314936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of cryoprecipitate-poor plasma as a replacement fluid for therapeutic plasma exchange in thrombotic thrombocytopenic purpura: a single center retrospective evaluation.
    Stefanello B; De Paula EV; Andrade Orsi F; Comenalli Marques JF; Gasparotto Roveri E; Pereira Colella M; Castro Ozelo M; Maria Annichino-Bizzacchi J; Addas-Carvalho M
    J Clin Apher; 2014 Dec; 29(6):311-5. PubMed ID: 24890787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immature platelet dynamics correlate with ADAMTS13 deficiency and predict therapy response in immune-mediated thrombotic thrombocytopenic purpura.
    Zhu ML; Reeves HM; Maitta RW
    Thromb Res; 2021 Feb; 198():72-78. PubMed ID: 33290885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
    Kato S; Fujimura Y
    Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
    Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
    Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.
    Peyvandi F; Lavoretano S; Palla R; Feys HB; Vanhoorelbeke K; Battaglioli T; Valsecchi C; Canciani MT; Fabris F; Zver S; Réti M; Mikovic D; Karimi M; Giuffrida G; Laurenti L; Mannucci PM
    Haematologica; 2008 Feb; 93(2):232-9. PubMed ID: 18223285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical study on five cases of thrombotic thrombocytopenic purpura complicating pregnancy.
    He Y; Chen Y; Zhao Y; Zhang Y; Yang W
    Aust N Z J Obstet Gynaecol; 2010 Dec; 50(6):519-22. PubMed ID: 21133861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura.
    Wu N; Liu J; Yang S; Kellett ET; Cataland SR; Li H; Wu HM
    Transfusion; 2015 Jan; 55(1):18-24. PubMed ID: 24953079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
    Furlan M; Robles R; Morselli B; Sandoz P; Lämmle B
    Thromb Haemost; 1999 Jan; 81(1):8-13. PubMed ID: 10348715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.